AzTrials
AzTrials

Depressive DisorderPhase 2NCT03932825

Nitrous Oxide for Major Depressive Disorder

A Phase 2 study testing Nitrous Oxide in people with Depressive Disorder and Major Depressive Disorder, run by Lingjiang Li at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study aims at investigating the persistence of antidepressant effect of Nitrous Oxide (N2O) for Treatment-Resistant Depression(TRD). The investigators also aim to assess the effect of N2O on the electroencephalograph, multimodal magnetic resonance imaging(MRI), blood cytokines, feces bacteria flora and… Read more about this study

Who is it for?
Ages 18 to 60 years
What is being tested?
Nitrous Oxide
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
44 participants
Where
1 siteChina
Study dates
1 Apr 2019to 31 Mar 2021
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Adult (≥18 years, both sexes), with ICD-10 criteria for MDD without psychosis, as determined by a structured clinical interview Mini International Neuropsychiatric Interview
  • Moderate to severe depression, as defined by a pretreatment score >17 on the HDRS-17 scale
  • TRD was defined as having had at least two adequate dose-duration, antidepressant medication failures in the current episode and a lifetime failure of at least three antidepressant medication trials.
  • Informed consent to participate in this study

Who cannot join

  • A history of bipolar disorder, schizophrenia, schizoaffective disorder, obsessive-compulsive disorder, panic disorder, or documented Axis II diagnoses; active suicidal intention, as determined by clinical interview
  • Active or recent (<12 months) substance abuse or dependence; excluding nicotine
  • Presence of acute medical illness that could interfere with study participation, including significant pulmonary disease
  • Acute severe suicidal ideation
  • Acute psychosis
  • Received ECT treatment within 6 months
Show all 9Show fewer
  • History of NMDA-antagonists (e.g., ketamine) intake
  • Pregnancy or breastfeeding
  • Any contraindications to the use of nitrous oxide (e.g., pneumothorax, middle ear occlusion, elevated intracranial pressure, chronic cobalamin or folate deficiency unless treated with folic acid or vitamin B12).

Trial locations and contacts

1 site in 1 country.

China1 site
  • Mental Health Institute & Faculty of Psychiatry of The Second Xiangya Hospital, Central South University

    Changsha, Hunan, 410001

Other trials in China

About this study

Official title: A Clinical Trial of Nitrous Oxide for Treatment-Resistant Major Depressive Disorder

This study aims at investigating the persistence of antidepressant effect of Nitrous Oxide (N2O) for Treatment-Resistant Depression(TRD). The investigators also aim to assess the effect of N2O on the electroencephalograph, multimodal magnetic resonance imaging(MRI), blood cytokines, feces bacteria flora and neuropsychological performance in patients with TRD. The investigators further aim to identify the predictors of N2O's antidepressant effeect using the above techniques.

Being tested
Nitrous Oxide, Placebo
Keywords
Nitrous Oxide, Laughing Gas
Medical subject headings
Depressive Disorder, Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant, Depression

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Nitrous OxideDrug

    Also called Laughing Gas, Xiao Qi, 笑气

    An 1-hour session of inhaled nitrous oxide at concentrations of 50%.

  • PlaceboDrug

    Also called Air oxygen mixture

    An 1-hour session of mixed oxygen-air gas(inspired oxygen concentration ~50%)

Study groups in NCT03932825
Study groupRoleWhat they receive
Air oxygen mixturePlacebo comparatorparticipants in this arm inhale mixed oxygen-air gas (inspired oxygen concentration ~50%).
Receives: Drug: Placebo
Nitrous oxideExperimentalParticipants in this group inhale mixed 50% nitrous oxide and 50% oxygen.
Receives: Drug: Nitrous Oxide

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Hamilton Depression Rating Scale-17 item (HDRS-17)

    Interview-based questionnaire used to measure the severity of depression. Consists of 17 items with a score calculated. Higher scores are associated with more severe depression.

    0 - 7 = Normal; 8 - 17 = Mild Depression; 18 - 24 = Moderate Depression; > 25 = Severe Depression; Maximum score = 52

    Measured: Baseline, 2hours, 24hours, 7days, 2weeks

  2. Change in QIDS-16-SR (Quick Inventory of Depressive Symptomatology-16 Self Report)

    This is a 16-item self report questionnaire that measures depressive symptoms. Improvement is reported in change in depressive score score ranges from 0-27, with higher numbers indicating more severe symptom reporting.

    Change is calculated by baseline plus/minus the value at the later time point

    Measured: Baseline, 2hours, 24hours, 7days, 2weeks

  3. Change in Visual Analog Scale-Depression (VAS-D)

    All patients are asked to fill out visual analog scale for depression (VAS-D) before and after the intervention. VAS-D is a self-report scale for ddepression severity, with 0 score indicating not at all depressed and 10 score indicating extremely depressed.

    Measured: Baseline, 2hours, 24hours, 7days, 2weeks

Secondary outcomes (11)
  1. Chang in Event Related Potentials (ERPs)

    The investigator employ 64-lead Event Related Potentials (ERPs) to assess the resting-state EEG signal and signals during specific neurocognitive processes related to tasks, including an emotional face recognition task, a dot probe task and a self-referential personality word memory task.

    Measured: Baseline, 24hours, 7days, 2weeks

  2. Change in voxel-based morphometry of grey matter, white matter as assessed by structural magnetic resonancce imaging.

    Participants will receive resting-state functional magnetic resonance imaging (MRI). Scans will be performed on a 3.0-T Siemens Magnetom Skyra scanner (Siemens Healthineers, Erlangen, Germany). During scanning, all participants were instructed to remain motionless, and to think of nothing in particular but to not fall asleep.

    Measured: Baseline, 24hours

  3. Change in Functional connectivity

    Change in Functional connectivity of the brain networks between baseline and after the inhaled Nitrous oxide 24hours as assessed by measure of connectivity in multimodal MRI.

    Measured: Baseline, 24hours

  4. Change in peripheral blood cytokines

    Peripheral blood sample will be collected and the concentration of IL-6, TNF-α, and CRP will be assessed.

    Measured: Baseline, 2hours, 24hours

  5. Change in feces bacterial flora

    The objective of investigator is to characterize gut microbiome in patients with TRD. To explore the specific diversity of gut microbiome.

    The stool samples were collected in the collection kits at the baseline, and were frozen at -80 °C. After the process of DNA Purification, 16S rRNA Gene Amplification and Illumina MiSeq sequencing, the study finally find the abundance and diversity of microbiota.

    Measured: Baseline

  6. Change in the TMT/A and B (Executive Function)

    Trail Making Test (TMT) is a cognitive test designed to assess scanning, visuomotor tracking, executive function, and cognitive flexibility. It consists of two parts, A and B: the patient must draw lines to connect consecutively numbered circles (part A) and then connect consecutively numbered and lettered circles alternating between the two sequences (part B). The time taken to complete the two parts is recorded. Part A assesses cognitive processing speed. The lower the score the faster the processing speed.

    Measured: Baseline, 24hours, 7days, 2weeks

  7. Change in Congruent STROOP Time to Complete (Executive Function)

    Stroop Colour Naming Test (STROOP) is a cognitive test designed to assess the ability to inhibit a prepotent response to reading words while performing a task that requires attention control. It comprises two sheets with 50 words on each, and each word is the name of a colour. On the first sheet, the Congruent STROOP Sheet, the word and ink colour match; on the Incongruent STROOP Sheet, the word and ink colour do not match. For each sheet, the patient has 4 minutes to name the ink colour of each word. When the patient finishes the sheet, or once 4 minutes is up, the clinician notes the time taken and counts the number of correct and incorrect responses. The scale ranges from 0-100, the higher score the greater the cognitive flexibility.

    Measured: Baseline, 24hours, 7days, 2weeks

  8. Digit-Span Test

    Score range 0-12 for each of for dimensions: Digit span forward, digit span backward, block span forward, block span backward. Higher scores indicate better cognitive performance.

    Measured: Baseline, 24hours, 7days, 2weeks

  9. Change in DSST (Number of Correct Symbols)

    Digit Symbol Substitution Test (DSST) is a cognitive test designed to assess psychomotor speed of performance requiring visual perception, spatial decision-making, and motor skills. It consists of 133 digits and requires the patient to substitute each digit with a simple symbol in a 90-second period. Each correct symbol is counted, and the total score ranges from 0 (less than normal functioning) to 133 (greater than normal functioning)." as a description of DSST.

    Measured: Baseline, 24hours, 7days, 2weeks

  10. Improvement on Snaith-Hamilton Pleasure Scale (SHAPS)

    The Snaith-Hamilton Pleasure Scale (SHAPS) assesses the anhedonia symptoms of MDD patients, with higher score indicating more severe anhedonia.

    Evaluating the patient's pleasure experience and choosing the degree of agreement with the happy response in some pleasant situations, and each item was rated on a 4-point scale."1 = Strongly agree, 2 = agree, 3 = disagree and 4 = strongly disagree" This scale evaluates the status of patients in the recent period of time, The total score of the scale is the sum of the scores of 14 items, with a total score of 14-56. The higher the total score, the more serious the anhedonia.

    Measured: Baseline, 2hours, 24hours, 7days, 2weeks

  11. Change in Hamilton Anxiety Rating Scale (HAM-A)

    Assessed via the Hamilton Anxiety Rating Scale (HAM-A). The HAM-A score ranges from 0 (no present anxiety) to 56 (maximum anxiety score).

    Measured: Baseline, 2hours, 24hours, 7days, 2weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 May 2019
  2. Study start1 Apr 2019
  3. Primary completion31 Mar 2021
  4. Study completion31 Mar 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
44 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03932825
Sponsor's protocol ID
18-05-04-XY-0001
Status last verified
Apr 2021
First submitted
20 Apr 2019
Last updated
8 Apr 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Nitrous Oxide in people with Depressive Disorder and Major Depressive Disorder, run by Lingjiang Li at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Apr 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Hamilton Depression Rating Scale-17 item (HDRS-17) (time frame: Baseline, 2hours, 24hours, 7days, 2weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2021.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in